Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Sepster who wrote (886)	11/3/1999 8:40:00 AM
From: Xpiderman	Respond to of 942

Euro Drug Stocks Up On Warner-AHP Report Wednesday November 3 8:23 AM ET By Jonathan Birt, European pharmaceuticals correspondent LONDON (Reuters) - An unconfirmed report that two of the U.S.'s biggest drugs groups could be in merger talks to form a new international champion sparked a rally among U.S. and European drug stocks Wednesday. The Wall Street Journal, citing people familiar with the situation, said Warner Lambert Co and American Home Products Corp (NYSE:AHP - news) were in advanced talks which could lead to an announcement of a $65 billion deal as soon as Thursday, though last-minute failure could not be ruled out. Shares in Warner-Lambert (NYSE:WLA - news), the U.S's ninth-largest group in terms of global prescription drug sales, traded up $6 9/16 in pre-opening New York dealing, while AHP, the U.S. number five, was up $3 5/8 at $54. The report had a knock-on effect in Europe's fragmented drugs industry, with the DJ Stoxx index of Europe's blue chip pharma stocks rising 2.17 percent, helping lift the broader market from early losses. The charge was led by a 4.36 percent gain in SmithKline Beecham Plc (NYSE:SBH - news), the Anglo-U.S. player whose ranking has slipped in the face of rival mergers, and which is seen as a highly attractive target. dailynews.yahoo.com